Scynexis
NASDAQ: SCYXDurham, US · 2 known investors
SCYNEXIS develops fungerp-based antifungal therapies, including SCY-247, for treating and preventing severe, progressive, and often fatal fungal diseases and antimicrobial-resistant infections. The company focuses on rare diseases affecting underserved patient populations.
Founders & leadership
YJ
Yves J. RibeillNamed on SEC filing
HD
Horace D. NalleNamed on SEC filing
PJ
Pamela J. KirbyNamed on SEC filing
LA
Laurent ArthaudNamed on SEC filing
MC
Mounia ChaouiNamed on SEC filing
PL
Patrick LangloisNamed on SEC filing
JN
Jean-Yves NothiasNamed on SEC filing
CF
Charles F. Osborne, Jr.Named on SEC filing
BS
Brian SchwabNamed on SEC filing
EP
Ed PenhoetNamed on SEC filing
AF
Ann F. HanhamNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$5.7M disclosed across 1 round · 2011
▶$5.7MraisedFeb 2012 · 11 investors · PharmaceuticalsRule 506(b)
▶$5.7MraisedFeb 2012 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Yves J. RibeillExecutive Officer, Director
- Horace D. NalleDirector
- Pamela J. KirbyDirector
- Laurent ArthaudDirector
- Mounia ChaouiDirector
- Patrick LangloisDirector
- Jean-Yves NothiasDirector
- Charles F. Osborne, Jr.Executive Officer
- Brian SchwabExecutive Officer
- Ed PenhoetDirector
- Ann F. HanhamDirector
- Offering amount
- $15M
- Amount sold
- $5.7M
- First sale
- Dec 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $224K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $224.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Scynexis do?
- SCYNEXIS develops fungerp-based antifungal therapies, including SCY-247, for treating and preventing severe, progressive, and often fatal fungal diseases and antimicrobial-resistant infections. The company focuses on rare diseases affecting underserved patient populations.
- Who are Scynexis's investors?
- Scynexis's investors include Decheng Capital, Foresite Capital.
- How much funding has Scynexis raised?
- Scynexis has disclosed $5.7M raised across 1 round.
- Where is Scynexis headquartered?
- Scynexis is headquartered in Durham, US.